Answers are grounded in this paper and cite their sources.
The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary (Checklist)” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.This protocol applies to neuroblastoma and related neuroblastic tumors only. There is no American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) TNM classification system for the staging of neuroblastoma. The International Neuroblastoma Pathology Classification and International Neuroblastoma Staging System are recommended.First priority should always be given to formalin-fixed tissue for morphologic evaluation. Special studies (eg, ploidy analysis, fluorescence in situ hybridization [FISH]) are critical to the molecular workup of neuroblastoma and require at least 100 mg of viable snap-frozen tissue as the second priority for workup (note A).For more information, contact: The Children's Oncology Group Biopathology Center; telephone: (614) 722-2890 or (800) 347-2486.MYCN gene amplification (>10 copies by Southern blot or FISH) in neuroblastoma tumor links to a poor prognosis of the patient. The MYCN gene is located in the short arm of chromosome 2. When amplified, it forms double minutes and homogeneously staining regions and produces an excess amount of N-Myc protein. The Myc-Max protein complex in the tumor cell nucleus has been shown to inhibit cellular differentiation and promote cellular proliferation and apoptosis/karyorrhexis.2 Hence, amplification is usually seen in undifferentiated and poorly differentiated neuroblastomas (Schwannian stroma-poor) and correlates with a higher MKI34 (note H). MYCN status of the tumor can be determined by the FISH method within a relatively short period of time after the surgery/biopsy. A double-staining procedure is recommended for comparing the number of chromosome 2 and MYCN signals in the same tumor nuclei for determining MYCN status. Increased MYCN signals associated with a like increase in number of chromosome 2 signals does not represent MYCN amplification.MYCN amplification is also correlated with advanced-stage tumors having chromosome 1p deletions, especially del 1p36.3. The deletion of 14q has also been shown to be unfavorable, as has the 11q deletion and 17q chromosomal gain.Determination of DNA index by flow cytometry also is very important. A DNA index near diploid/tetraploid is unfavorable, whereas hyperdiploid (near-triploid) tumors have a good prognosis. However, prognostic effects of DNA index are reported to be limited to those patients diagnosed at less than 1 year of age.5Higher expression of TrkA (high-affinity nerve growth factor receptor) favors a good prognosis.1 MYCN-amplified tumors usually have a lower expression of TrkA.Although MYCN FISH studies can be performed on touch preparations, and ploidy analysis can be performed on frozen tissue also available for touch preparations, cytogenetics requires fresh tissue. A minimum of 100 mg, and preferably 1 g, of fresh tumor is required for these purposes (note G).The clinical presentation of neuroblastoma may provide valuable information in assessing biologic risk. The abdomen is the most common primary site of neuroblastoma, with more than 76% of tumors arising either in the adrenals or, less commonly, in the paramidline sympathetic chains.1 In older children, an abdominal mass usually represents an adrenal primary tumor, whereas in infants, it often represents hepatomegaly secondary to metastatic disease.The posterior mediastinum is the second most common primary site, and respiratory symptoms predominate. Cervical neuroblastoma presents as a mass with or without Horner syndrome.6 All neuroblastomas regardless of biologic risk can extend along radicular nerves, through spinal foramina, and into the epidural space, forming a dumbbell-shaped mass.Because the spinal cord extends to the level of the T12 to L1 vertebrae, tumors above this level are more likely to cause cord compression and paralysis, bladder and bowel dysfunction, or numbness. Similarly, neuroblastomas primary in the pelvis may present with constipation or urinary symptoms, including dysuria, infection, flank pain, or urinary retention.7The opsoclonus-myoclonus syndrome is a prime example of a paraneoplastic manifestation of neuroblastoma. Patients with this syndrome usually have an excellent prognosis. This is thought to be secondary to cross-reaction of antineuroblastoma antibodies with the Purkinje cells of the cerebellum. As many as 70% of such patients have permanent neurologic deficits despite curative tumor resection.8Ultrasound scans are the most common initial screening study to confirm a palpable abdominal or pelvic mass.9 The most useful imaging study is computerized axial tomography done with simultaneous oral and intravenous contrast.10 This gives excellent information about the primary tumor, including location, vascular encasement, and the status of regional lymph nodes. Hepatic and even gross bony metastases can be visualized, as can pulmonary metastases (the latter is an extremely rare site for dissemination).1 Magnetic resonance imaging can give valuable information about vascular and hepatic involvement and can help to determine tumor resectability, but it is difficult to perform in active young children.A diphosphate bone scan and a MIBG scan are requisite to assess the bone and bone marrow for distant disease.11 A positive bone scan or bone survey indicates cortical bone involvement and is a negative prognostic factor; these patients are at high risk. Approximately 85% of neuroblastomas will take up MIBG.1Urinary catecholamine secretion is increased in neuroblastoma and is useful as a confirmatory diagnostic marker. Serial determinations are used to assess therapeutic response and identify recurrence. Vanillylmandelic acid and homovanillic acid are the 2 catecholamine metabolites commonly measured12 via high-performance liquid chromatography. In 1 study,13 the sensitivity and specificity of homovanillic acid for detection of neuroblastoma were 72% and 98%, respectively; corresponding figures for vanillylmandelic acid were 80% sensitivity and 97% specificity. On rare occasions, increased urinary catecholamine secretion may not be seen with an undifferentiated neuroblastoma.Rarely, the first diagnostic sign of neuroblastoma may be hypersecretion of vasoactive intestinal peptide with associated watery diarrhea.14Serum determinations are useful to help predict prognostic risk. These include serum lactic dehydrogenase, neuron-specific enolase, and ferritin.15 Ferritin levels are the most important diagnostic marker of the 3, with an elevation above normal (before transfusion) associated with a worse prognosis. Reference ranges are dependent on the individual laboratory, but an upper normal limit of 142 ng/mL frequently is reported.16 Serial lactic dehydrogenase levels correlate with disease activity, and pretreatment values of more than 1000 U/L are associated with a worse prognosis.17 Serum levels of neuron-specific enolase more than 30 ng/mL also are associated with a worse prognosis.18Schwann cells: S100 protein positiveThe following are positive in a variable proportion of cases:The following are usually negative:A cell surface glycoprotein, p30/32 (product of the MIC2 gene detected by CD99 antibodies), common in peripheral primitive neuroectodermal tumor/Ewing sarcoma, usually is negative in neuroblastoma. In contrast, tyrosine hydroxylase commonly is positive for neuroblastoma and negative for peripheral primitive neuroectodermal tumor/Ewing sarcoma.Undifferentiated cells (in poorly differentiated subtype) may, on rare occasions, express vimentin and have rhabdoid morphology.Ultrastructural studies are still of value in the diagnosis of relatively undifferentiated neuroblastoma, where the diagnosis is not readily evident by light microscopic study or urinary catecholamine study, especially given the variable specificity of immunostaining. Diagnostic criteria include dense core granules of neurosecretory type and cell processes (primitive neurites) containing typically arranged microtubules.It is recommended that the International Neuroblastoma Classification1920 described later should be used when describing tumor samples.There are 4 categories in this group of tumors:Within each category, 1 or more subtypes are recognized.Microscopically, tumors in the neuroblastoma category are composed of neuroblastic cells that form groups or nests separated by delicate, often incomplete stromal septa without or with limited Schwannian proliferation; whereas tumors in the ganglioneuroblastoma, intermixed category and the ganglioneuroma category are characterized by a presence of ganglioneuromatous tissue, where mature and/or maturing ganglion cells are individually scattered in a background of highly developed Schwannian stroma. Tumors in the ganglioneuroblastoma, nodular category are composed of multiple clones: 1 shows an appearance of either ganglioneuroblastoma, intermixed or ganglioneuroma, and the other(s) show appearance of neuroblastoma.Three subtypes are distinguished.Neuropil absent; no tumor cell differentiation; diagnosis relies heavily on ancillary techniques, such as immunohistochemistry, electron microscopy, and/or molecular/cytogenetics.Neuropil background evident; 5% or fewer tumor cells show a feature of differentiating neuroblasts with a synchronous differentiation of nucleus (enlarged, vesicular, with a single prominent nucleolus) and cytoplasm (conspicuous, eosinophilic or amphophilic, and 2 times larger in diameter than nucleus).More than 5% of tumor cells show an appearance of differentiating neuroblasts (may be accompanied by mature ganglion-like cells), and neuropil is usually abundant; some tumors can show substantial Schwannian stromal formation, frequently at their periphery, and a transition zone between neuroblastomatous and ganglioneuromatous region can develop, although this zone does not have well-defined borders and comprises less than 50% of the tumor.Ganglioneuromatous (stroma-rich) component of tumor exceeds 50%; intermixed or randomly distributed pattern of microscopic neuroblastic nests present, consisting of cells in various stages of differentiation (neuroblasts, differentiating neuroblasts, maturing ganglion cells); abundant neuropil; macroscopic hemorrhagic nodules are absent.Two subtypes are included; neuroblastic cells (differentiating neuroblasts, maturing and mature ganglion cells) in the tumor tissue do not form microscopic nests but are individually distributed in the Schwannian stroma.Predominately ganglioneuromatous stroma; minor, scattered groups of differentiating neuroblasts or maturing ganglion cells along with completely mature ganglion cells.Mature Schwannian stroma and ganglion cells; neuritic fascicular processes, accompanied by Schwann cells and perineurial cells; absence of neuroblastomatous component in complete maturation; satellite cells accompany mature ganglion cells.Ganglioneuroblastoma, intermixed (stroma-rich) or ganglioneuroma (stroma-dominant) with macroscopic neuroblastic nodules (stroma-poor and usually hemorrhagic); border between nodule and stroma-rich or stroma-dominant region is often abrupt microscopically but may instead be more gradual; the neuroblastoma component may be found in a metastatic tumor where the primary is ganglioneuroblastoma, intermixed or ganglioneuroma.Neuroblastic cells evident; sample insufficient for categorization into 1 of the 4 basic types. A small biopsy taken from a large tumor can result in this designation.Tumor diagnosis of neuroblastoma (Schwannian stroma-poor); subtyping not possible because of poor quality of sample or section.Tumor diagnosis of ganglioneuroblastoma (Schwannian stroma-rich); subtyping not possible because of a limited amount of tissue for evaluation or extensive calcification of tumor.* Ganglioneuroblastomas are highly variable in both number of neuroblasts and their extent of differentiation. Variability is seen between tumors, between microscopic fields in the same tumor, and occasionally between the primary and metastatic tumors. Ganglioneuroblastoma diagnostic criteria include (1) mature Schwannian stromal component with individually scattered mature and/or maturing ganglion cells, and (2) a neuroblastic component.The presence of calcification in any amount in the tumor tissue tends to indicate an improved prognosis of the patient.21In the complete macroscopic evaluation of the specimen, sections should be obtained from central and peripheral areas of the tumor according to common guidelines (at least 1 tumor section per centimeter in the longest dimension and sections from the inked surgical margins).19The genetic and morphologic heterogeneity of neuroblastoma requires extensive biologic and histologic study of the tumor. If practical, the entire tumor should be examined microscopically to facilitate the detection of any neuroblastic nodules that may have been overlooked on gross examination. In addition to the tissue taken for histologic examination as described, the International Neuroblastoma Pathology Committee recommends sampling a neuroblastic surgical specimen for biologic studies as follows.19A minimum of 2 samples (A and B, each 1 × 1 × 1 cm) should be taken, preferably from morphologically different areas. Samples A and B are split into 4 pieces:The above recommendations are applicable when the entire or a large proportion of the tumor is resected, or when 1 or more large biopsy specimens are available. If the amount of tumor tissue is restricted, morphologic diagnosis is the prime consideration. Imprints (for FISH study of MYCN) should always be made from fresh tumor tissue.If, as a minimum procedure, only core biopsies are performed, they should be multiple (2 to 4, for formalin fixation and snap-freezing), preferably concomitant with fine-needle aspiration specimens for FISH study of MYCN. A minimum of 100 mg snap-frozen tissue may be necessary for ploidy study by flow cytometry. Such specimens are usually not sufficient for prognostic evaluation histopathologically.19The MKI is the number of mitoses and karyorrhectic nuclei per 5000 neuroblastic cells. It is a useful prognostic indicator for tumors in the neuroblastoma (Schwannian stroma-poor) category and should be determined as an average of all tumor sections available. The method described by Joshi et al22 can be used to calculate MKI without the need to count 5000 cells. In summary, cellular density is usually estimated under low power, and the tumor is classified as either a dense (700–900 cells/×400 high-power field [HPF]),* moderate (400–600 tumor cells/HPF),* sparse (100–300 cells/HPF),* or mixed category (a mixed tumor has variable cellularity under different HPFs). Once categorized, random HPFs are chosen to count mitotic and karyorrhectic cells. High-power fields on specimens in the mixed category are selected to be proportional to the cellular density in the specimen; for example, in a sample with 70% dense cellularity and 30% sparse cellularity, 70% of the HPFs should be in dense areas and 30% in sparse areas. In highly cellular tumors, the MKI can be determined in 6 to 8 HPFs, whereas in tumors with low cellularity and prominent neuropil, 20 or more HPFs may be necessary. Specimens are assigned to 1 of 3 prognostic categories:* Numbers of neuroblastic cells in each HPF (denominator for MKI determination) can vary based on the type of your microscope (some practice required for assessing the number of neuroblastic cells in your HPF). Numbers of tumor cells listed above in the parentheses are for the microscope with a regular ocular. With a super-wide field type of ocular, you may be able to have 1200 to 1500 cells per HPF in a dense category.The International Neuroblastoma Staging System is accepted as universally applicable and should always be recorded for new patients.1 The core of clinical staging is the size of the primary tumor, locoregional lymph node status, and the presence of distant metastases.Risk group assessment can be defined by clinical and biologic variables. A simplified approach is described using either pathologic variables combined with age (Table 1)2023 or a compendium of biologic and clinical risk factors (Table 2).1 Also included is a risk-grouping scheme for clinical trials of the Children's Oncology Group Neuroblastoma Studies (Table 3) based on the combination of clinical stage, age at diagnosis, MYCN status, histopathology classification, and DNA index (only for infants) (Table 3).The International Neuroblastoma Pathology Classification20 uses age, neuroblastic maturation, and MKI as prognostic indicators. Unfavorable indicators include undifferentiated neuroblastoma (especially in older patients) and high MKI.
No takes yet. Share an insight, caveat, or question.
Qualman et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: